State of Tennessee Department of Treasury Cuts Stake in Repligen Co. (NASDAQ:RGEN)

State of Tennessee Department of Treasury lessened its stake in shares of Repligen Co. (NASDAQ:RGEN) by 2.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,426 shares of the biotechnology company’s stock after selling 520 shares during the period. State of Tennessee Department of Treasury’s holdings in Repligen were worth $2,652,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in RGEN. UMB Bank n.a. increased its stake in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Repligen in the fourth quarter worth $216,000. Van ECK Associates Corp raised its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after buying an additional 3,066 shares during the period. Stephens Investment Management Group LLC lifted its position in shares of Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock valued at $77,267,000 after buying an additional 37,057 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Repligen during the 3rd quarter worth $233,000. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $144.75 on Monday. The stock’s 50-day simple moving average is $139.80 and its two-hundred day simple moving average is $145.94. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The firm has a market capitalization of $8.13 billion, a P/E ratio of -283.82, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. As a group, equities analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, April 17th. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Finally, Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen currently has a consensus rating of “Hold” and an average price target of $176.82.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.